Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study

NCT01719835 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT01719835
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01719835 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2012
Completion date
August 31, 2022
Enrollment
87 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-negative, angioimmunoblastic t-cell lymphoma, enteropathy-associated t-cell lymphoma, hepatosplenic gamma/ delta t-cell lymphoma, peripheral t-cell lymphoma nos